6 news items
Immunocore announces randomization of first patient in the global, registrational Phase 3 clinical trial testing brenetafusp for the treatment of first-line advanced or metastatic cutaneous melanoma
IMCR
18 Jun 24
. It is the most aggressive skin carcinoma and is associated with the vast majority of skin cancer-related mortality. The majority of patients with CM
Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024
IMCR
31 May 24
Cutaneous melanoma (CM) is the most common form of melanoma. It is the most aggressive skin carcinoma and is associated with the vast majority of skin
Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanoma
IMCR
29 May 24
melanoma (CM) is the most common form of melanoma. It is the most aggressive skin carcinoma and is associated with the vast majority of skin cancer
Analyst Expectations For Immunocore Hldgs's Future
IMCR
24 May 24
are the United Kingdom and the United States, of which the majority of its revenue comes from the United States.
Immunocore Hldgs's Financial Performance
Where Immunocore Hldgs Stands With Analysts
IMCR
29 Apr 24
, infectious and autoimmune diseases. Its geographical segments are the United Kingdom and the United States, of which the majority of its revenue
z0onw9rlh88mwtp10i2dtujyz9lc6v393s50wmb
IMCR
11 Apr 24
States, of which the majority of its revenue comes from the United States.
A Deep Dive into Immunocore Hldgs's Financials
Market
- Prev
- 1
- Next